Stay updated on De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial
Sign up to get notified when there's something new on the De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial page.

Latest updates to the De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange Detected- The Study Details page now shows the Results First Posted date and results data, including primary/secondary outcomes and adverse events, with updated enrollment and completion dates. - Updated sections reflect the trial's progress and outcomes; additional QoL and biomarker data are also listed.SummaryDifference0.4%

- Check18 days agoNo Change Detected
- Check39 days agoChange DetectedMajor changes: add government funding/status notice and version v3.2.0; remove a specific resource and older version v3.1.0.SummaryDifference0.9%

- Check47 days agoChange DetectedTerminology refined from “Head and neck squamous cell carcinoma” to “Squamous cell carcinoma of the head and neck” and version updated from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check61 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2; 'Back to Top' removed.SummaryDifference0.0%

- Check68 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.0%

- Check75 days agoChange DetectedThe web page has been updated to include new resources related to head and neck cancer, along with the addition of a facility name and location details, while several previous terms and categories related to antineoplastic agents and immune mechanisms have been removed.SummaryDifference1%

Stay in the know with updates to De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the De-Escalated Radiation + Nivolumab in P16+ Oropharynx Cancer Clinical Trial page.